Christopher Ianelli

Chris conceptualized and founded iSpecimen to address the growing need for human biospecimens by the life science research communities. He is responsible for the company’s growth and performance since its inception and actively oversees the corporate direction and many of the new strategic partnerships. Chris has successfully managed iSpecimen technology development and its expansion into additional partner supply sites.

Prior to launching iSpecimen, Chris served as Managing Director at Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. Chris was also a co-founder of Health Insight Technologies (now Humedica), a novel healthcare informatics company. Prior to this, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors (BMSA), a healthcare investment research firm acquired by Leerink Swann. He received both his PhD in Immunology and his MD from Tufts University and completed his residency training, including one year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.